Core Viewpoint - The article discusses the successful results of the DREAMS-3 clinical trial for the dual receptor agonist IBI362 (Mastrutide), highlighting its efficacy in reducing HbA1c and body weight in Chinese patients with type 2 diabetes and obesity [6][8]. Group 1: Clinical Trial Results - The DREAMS-3 trial demonstrated that 48.0% of patients in the Mastrutide group achieved HbA1c < 7.0% and a weight loss of ≥10% by week 32, significantly outperforming the Semaglutide group at 21.0% (P < 0.0001) [6]. - The mean change in HbA1c from baseline at week 32 was -2.03% for the Mastrutide group and -1.84% for the Semaglutide group, with both showing statistically significant results (P < 0.05) [6]. - The average percentage weight loss from baseline at week 32 was 10.29% for Mastrutide and 6.00% for Semaglutide, indicating a notable difference in efficacy [6]. Group 2: Study Design and Demographics - The DREAMS-3 trial was a multicenter, randomized, open-label Phase III study involving 349 Chinese participants with early-stage type 2 diabetes and obesity, with an average age of 42.4 years and an average disease duration of 1.8 years [8]. - Participants had a baseline HbA1c of 8.02%, a baseline weight of 90.47 kg, and a baseline BMI of 32.98 kg/m², indicating a population with significant metabolic challenges [8]. - The study randomized participants to receive either 6 mg of Mastrutide or 1 mg of Semaglutide for 32 weeks, followed by an extension phase based on weight loss outcomes [8]. Group 3: Safety Profile - The overall safety profile of Mastrutide was consistent with previous clinical studies, with no new safety signals identified during the trial [6]. - Gastrointestinal adverse events were the most common, primarily mild to moderate in severity, indicating a manageable safety profile for patients [6].
速递｜48%受试者减重超10%！信达生物玛仕度肽重磅新结果发布